ArticleRespiratory research2020
A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Article in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Economic burden and cost drivers of interstitial lung disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- A narrative review on the interplay between interstitial lung disease and obstructive sleep apnea: Mechanisms, clinical implications, and management strategies.Sleep medicine: X · 2026Review
- Peri-transplant frailty changes impact survival in interstitial lung diseases.ERJ open research · 2026Article
- An investigation of causality between obstructive sleep apnea and interstitial lung disease: Insights from two-sample mendelian randomization.Respiratory medicine · 2025Article
- Classification of Patients Based on Dyspnea and Desaturation During Exercise in Interstitial Lung Disease.Respiratory care · 2025Article
- Risk Factors for Hospital Readmission in Patients With Interstitial Lung Disease.Respiratory care · 2024Article
- Phenotypic subtypes of fibrotic hypersensitivity pneumonitis identified by machine learning consensus clustering analysis.Respiratory research · 2024Article
- The prognostic value of gastroesophageal reflux disorder in interstitial lung disease related hospitalizations.Respiratory research · 2023Article
- Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts.Nature communications · 2023Article
- Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.Medicina (Kaunas, Lithuania) · 2023Article
- Editorial: Fibrotic tissue remodeling as a driver of disease pathogenesis.Frontiers in molecular biosciences · 2023Article
- Clusters of comorbidities in fibrotic hypersensitivity pneumonitis.Respiratory research · 2022Article
- What Constitutes Family Ties? Exposures and Disease Phenotypes in Familial Pulmonary Fibrosis.Annals of the American Thoracic Society · 2022Article
- Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort.The Lancet. Digital health · 2022Observational
- Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore.Journal of thoracic disease · 2022Article
- OSA and Chronic Respiratory Disease: Mechanisms and Epidemiology.International journal of environmental research and public health · 2022Review
- Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures.ERJ open research · 2022Article
- Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From aFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComorbidities are frequent and have been associated with poor quality of life, increased hospitalizations, and mortality in patients with interstitial lung disease (ILD). However, it is unclear how comorbidities lead to these negative outcomes and whether they could influence ILD disease progression. The goal of this study was to identify clusters of patients based on similar comorbidity profiles and to determine whether these clusters were associated with rate of lung function decline and/or mortality.
methodsPatients with a major fibrotic ILD (idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis, connective tissue disease-associated ILD, and unclassifiable ILD) from the CAnadian REgistry for Pulmonary Fibrosis (CARE-PF) were included. Hierarchical agglomerative clustering of comorbidities, age, sex, and smoking pack-years was conducted for each ILD subtype to identify combinations of these features that frequently occurred together in patients. The association between clusters and change in lung function over time was determined using linear mixed effects modeling, with adjustment for age, sex, and smoking pack-years. Kaplan Meier curves were used to assess differences in survival between the clusters.
resultsDiscrete clusters were identified within each fibrotic ILD. In IPF, males with obstructive sleep apnea (OSA) had more rapid decline in FVC %-predicted (- 11.9% per year [95% CI - 15.3, - 8.5]) compared to females without any comorbidities (- 8.1% per year [95% CI - 13.6, - 2.7]; p = 0.03). Females without comorbidities also had significantly longer survival compared to all other IPF clusters. There were no significant differences in rate of lung function decline or survival between clusters in the other fibrotic ILD subtypes.
conclusionsThe combination of male sex and OSA may portend worse outcomes in IPF. Further research is required to elucidate the interplay between sex and comorbidities in ILD, as well as the role of OSA in ILD disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.